Teva Pharmaceutical Industries Ltd (ADR) logo Teva Pharmaceutical Industries Ltd (ADR) (NASDAQ:TEVA) is set to release its Q114 earnings data on Thursday, May 1st. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares after opening at $49.59 moved to $49.91 on last trade day and at the end of the day closed at $48.86. Company price to sales ratio in past twelve months was calculated as 2.35 and price to cash ratio as 46.03. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) showed a negative weekly performance of -3.57%.
Johnson & Johnson (NYSE:JNJ) is stopping sales of its laparoscopic power morcellators, devices used to remove growths in the uterus, a week after the FDA warned that electronic surgical tools can spread cancer to other parts of the body. Johnson & Johnson (NYSE:JNJ) shares advanced 0.26% in last trading session and ended the day on $101.29. JNJ return on equity ratio is recorded as 21.50% and its return on assets is 11.90%. Johnson & Johnson (NYSE:JNJ) yearly performance is 22.36%.
It is not that AstraZeneca plc (ADR) (NYSE:AZN) has already accepted a bid for its takeover by the U.S. pharmaceutical giant Pfizer Inc. (NYSE:PFE). However, British lawmakers are already concerned about several things including potential job loss following what could become the largest foreign acquisition of a British company. AstraZeneca plc (ADR) (NYSE:AZN) shares moved up 2.52% in last trading session and was closed at $79.05, while trading in range of $78.15 – $79.21. AstraZeneca plc (ADR) (NYSE:AZN) year to date (YTD) performance is 36.98%.
Reckitt Benckiser Group said on Wednesday it was no longer in active talks with Merck & Co Inc. (NYSE:MRK) about buying its consumer health business, leaving Germany’s Bayer as a leading contender for the $14 billion business. Merck & Co., Inc. (NYSE:MRK) weekly performance is 1.84%. On last trading day company shares ended up $58.56. Merck & Co., Inc. (NYSE:MRK) distance from 50-day simple moving average (SMA50) is 4.27%. Analysts mean target price for the company is $57.78.
Gilead Sciences, Inc. (NASDAQ:GILD) total revenues for the first quarter of 2014 increased to $5.00 billion from $2.53 billion for the first quarter of 2013. Net income for the first quarter of 2014 was $2.23 billion, or $1.33 per diluted share compared to $722.2 million, or $0.43 per diluted share for the first quarter of 2013. Non-GAAP net income for the first quarter of 2014 was $2.49 billion, or $1.48 per diluted share compared to $801.9 million, or $0.48 per diluted share for the first quarter of 2013. Gilead Sciences, Inc. (NASDAQ:GILD) shares after opening at $76.15 moved to $78.67 on last trade day and at the end of the day closed at $78.49. Company price to sales ratio in past twelve months was calculated as 8.83 and price to cash ratio as 17.60. Gilead Sciences, Inc. (NASDAQ:GILD) showed a positive weekly performance of 6.27%.